French-based biopharmaceutical company Poxel has reported positive first stage Phase I clinical trial results of PXL770 to treat type 2 diabetes.
PXL770 acts as a direct adenosine monophosphate-activated protein kinase (AMPK) activator.
The AMPK is instrumental in energy metabolism acting as an energy sensor regulating glucose and lipid levels.
Its activation replicates the impacts of long-term exercise and has a key role in diabetes management, especially for patients vulnerable to cardiac risk factors.
The first stage of the Phase I trial involved 64 healthy male subjects and evaluated the safety, tolerability and pharmacokinetics aspects of the PXL770 administered in six single ascending oral doses.
The results have showed a favourable safety and tolerability profile of the drug candidate with no reported adverse events or safety signals.
The pharmacokinetic evaluation demonstrated that PXL770 plasma exposure increases in a dose dependent manner with a consistent effect across individuals after being orally administered.
Poxel CEO Thomas Kuhn said: "PXL770 is a first-in-class product with a unique mode of action, which we believe targets an important mechanism for the treatment of type 2 diabetes, as well as other metabolic disorders."
The company is planning to conduct the second stage of the trial to evaluate the safety, tolerability, pharmacokinetics aspects and target engagement of the PXL770 during multiple ascending doses administration.